Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana

Malaria Journal

Volumn 16, Issue 1, 2017, Pages

  Acquah, Festus K ^a   Obboh, Evans K ^b   Asare, Kwame ^b   Boampong, Johnson N ^b   Nuvor, Samuel Victor ^b   Singh, Susheel K ^c,d   Theisen, Michael ^c,d   Williamson, Kim C ^e,f   Amoah, Linda Eva ^a  

^a University of Ghana   (Ghana)

^b UNIVERSITY OF CAPE COAST   (Ghana)

^c STATENS SERUM INSTITUT   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

^f UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Lactococcus lactis; Malaria; Pfs230; Pfs48 45; Seropositive; Transmission blocking

Indexed keywords

EPITOPE; PARASITE ANTIGEN; PLASMODIUM FALCIPARUM SEXUAL STAGE ANTIGEN 230; PLASMODIUM FALCIPARUM SEXUAL STAGE ANTIGEN 45; PLASMODIUM FALCIPARUM SEXUAL STAGE ANTIGEN 48; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; MALARIA VACCINE; PROTOZOAL PROTEIN;

ADOLESCENT; ADULT; AGE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PURIFICATION; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE EXPRESSION SYSTEM; GHANA; HUMAN; INFANT; LACTOCOCCUS LACTIS; MAJOR CLINICAL STUDY; MALARIA; MALE; NEWBORN; NONHUMAN; SEROPREVALENCE; GENETICS; IMMUNOLOGY; MALARIA FALCIPARUM; MIDDLE AGED; PARASITOLOGY; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; SEROEPIDEMIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ANTIGENS, BACTERIAL; CHILD; CHILD, PRESCHOOL; FEMALE; GHANA; HUMANS; INFANT; LACTOCOCCUS LACTIS; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 85026665830     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-017-1955-0     Document Type: Article

References (36)

1. WHO. World malaria report 2016. Geneva: World Health Organization; 2016.
2. Kaslow DC. Transmission-blocking vaccines: uses and current status of development. Int J Parasitol. 1997;27:183-9.
3. Saeed M, Roeffen W, Alexander N, Drakeley CJ, Targett GA, Sutherland CJ. Plasmodium falciparum antigens on the surface of the gametocyte-infected erythrocyte. PLoS ONE. 2008;3:e2280.
4. Carter R, Graves PM, Keister DB, Quakyi IA. Properties of epitopes of Pfs 48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum. Parasite Immunol. 1990;12:587-603.
5. Outchkourov N, Vermunt A, Jansen J, Kaan A, Roeffen W, Teelen K, et al. Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies. J Biol Chem. 2007;282:17148-56.
6. Read D, Lensen AH, Begarnie S, Haley S, Raza A, Carter R. Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement-fixing. Parasite Immunol. 1994;16:511-9.
7. Williamson KC, Keister DB, Muratova O, Kaslow DC. Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Mol Biochem Parasitol. 1995;75:33-42.
8. Ouedraogo AL, Roeffen W, Luty AJ, de Vlas SJ, Nebie I, Ilboudo-Sanogo E, et al. Naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs48/45 and Pfs230 in an area of seasonal transmission. Infect Immun. 2011;79:4957-64.
9. Bousema JT, Drakeley CJ, Kihonda J, Hendriks JC, Akim NI, Roeffen W, et al. A longitudinal study of immune responses to Plasmodium falciparum sexual stage antigens in Tanzanian adults. Parasite Immunol. 2007;29:309-17.
10. Bousema T, Roeffen W, Meijerink H, Mwerinde H, Mwakalinga S, van Gemert GJ, et al. The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania. PLoS ONE. 2010;5:e14114.
11. Singh SK, Roeffen W, Andersen G, Bousema T, Christiansen M, Sauerwein R, et al. A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies. Vaccine. 2015;33:1981-6.
12. Roeffen W, Theisen M, van de Vegte-Bolmer M, van Gemert G, Arens T, Andersen G, et al. Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants. Malar J. 2015;14:443.
13. Baldwin SL, Roeffen W, Singh SK, Tiendrebeogo RW, Christiansen M, Beebe E, et al. Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2. 6C multi-stage vaccine antigen. Vaccine. 2016;34:2207-15.
14. Outchkourov NS, Roeffen W, Kaan A, Jansen J, Luty A, Schuiffel D, et al. Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proc Natl Acad Sci USA. 2008;105:4301-5.
15. Theisen M, Roeffen W, Singh SK, Andersen G, Amoah L, van de Vegte-Bolmer M, et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine. 2014;32:2623-30.
16. Kushwaha A, Rao PP, Suresh RP, Chauhan VS. Immunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli. Parasite Immunol. 2001;23:435-44.
17. Tachibana M, Wu Y, Iriko H, Muratova O, MacDonald NJ, Sattabongkot J, et al. N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity. Clin Vaccine Immunol. 2011;18:1343-50.
18. Farrance CE, Rhee A, Jones RM, Musiychuk K, Shamloul M, Sharma S, et al. A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum. Clin Vaccine Immunol. 2011;18:1351-7.
19. Asare KK, Boampong JN, Afoakwah R, Ameyaw EO, Sehgal R, Quashie NB. Use of proscribed chloroquine is associated with an increased risk of pfcrt T76 mutation in some parts of Ghana. Malar J. 2014;13:246.
20. District Health Information Management System (DHIMS). GHS, Ghana. 2013. http://solutionscenter.nethope.org/assets/collaterals/DHIMS2-login-page.png. Accessed 20 Apr 2015.
21. Williamson KC, Criscio MD, Kaslow DC. Cloning and expression of the gene for Plasmodium falciparum transmission-blocking target antigen, Pfs230. Mol Biochem Parasitol. 1993;58:355-8.
22. Ravn P, Arnau J, Madsen SM, Vrang A, Israelsen H. Optimization of signal peptide SP310 for heterologous protein production in Lactococcus lactis. Microbiology. 2003;149:2193-201.
23. Holo H, Nes IF. Transformation of Lactococcus by electroporation. Electroporation Protoc Microorg. 1995;47:195-199.
24. Kapust RB, Tozser J, Fox JD, Anderson DE, Cherry S, Copeland TD, et al. Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. Protein Eng. 2001;14:993-1000.
25. Baidjoe A, Stone W, Ploemen I, Shagari S, Grignard L, Osoti V, et al. Combined DNA extraction and antibody elution from filter papers for the assessment of malaria transmission intensity in epidemiological studies. Malar J. 2013;12:272.
26. Artimo P, Jonnalagedda M, Arnold K, Baratin D, Csardi G, de Castro E, et al. ExPASy: SIB bioinformatics resource portal. Nucleic Acids Res. 2012;40:W597-603.
27. Price R, Nosten F, Simpson JA, Luxemburger C, Phaipun L, ter Kuile F, et al. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg. 1999;60:1019-23.
28. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;24:377-410.
29. Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, et al. Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine. N Engl J Med. 2015;373:2025-37.
30. Bustamante PJ, Woodruff DC, Oh J, Keister DB, Muratova O, Williamson KC. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity. Parasite Immunol. 2000;22:373-80.
31. Ayanful-Torgby R, Oppong A, Abankwa J, Acquah F, Williamson KC, Amoah LE. Plasmodium falciparum genotype and gametocyte prevalence in children with uncomplicated malaria in coastal Ghana. Malar J. 2016;15:592.
32. Bousema JT, Roeffen W, van der Kolk M, de Vlas SJ, van de Vegte-Bolmer M, Bangs MJ, et al. Rapid onset of transmission-reducing antibodies in javanese migrants exposed to malaria in papua, indonesia. Am J Trop Med Hyg. 2006;74:425-31.
33. Jones S, Grignard L, Nebie I, Chilongola J, Dodoo D, Sauerwein R, et al. Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates. J Infect. 2015;71:117-27.
34. Dinko B, King E, Targett GA, Sutherland CJ. Antibody responses to surface antigens of Plasmodium falciparum gametocyte-infected erythrocytes and their relation to gametocytaemia. Parasite Immunol. 2016;38:352-64.
35. Niederwieser I, Felger I, Beck HP. Limited polymorphism in Plasmodium falciparum sexual-stage antigens. Am J Trop Med Hyg. 2001;64:9-11.
36. Aurrecoechea C, Brestelli J, Brunk BP, Dommer J, Fischer S, Gajria B, et al. PlasmoDB: a functional genomic database for malaria parasites. Nucleic Acids Res. 2009;37:D539-43.